Insights on the Contraceptives Global Market to 2028 - Increasing Awareness About Sexually Transmitted Diseases Presents Opportunities
July 30, 2021 09:13 ET
|
Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "Contraceptives Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, End User, Distribution Channel" report has been added to...
Worldwide Contraceptive Devices Industry to 2025 - Players Include Allergan Plc, Bayer Healthcare and Cooper Surgical Among Others
February 04, 2021 06:48 ET
|
Research and Markets
Dublin, Feb. 04, 2021 (GLOBE NEWSWIRE) -- The "Contraceptive Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
March 14, 2018 07:45 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended...
Global Intra-Uterine Contraceptive Device (IUDs), a Safer Way to Birth Control Measure with Reversible Contraception is Expected to Reach USD 5.27 Billion by 2023
January 31, 2018 06:49 ET
|
Energias Market Research
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- The global intra-uterine contraceptive device market is expected to grow steadily from USD 3.80 billion in 2016 to USD 5.27 billion in 2023, at a CAGR of...
Agile Therapeutics to Host First Analyst Day on October 10, 2017
October 02, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
August 03, 2017 08:23 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced the pricing of its underwritten public...
Agile Therapeutics Announces Proposed Offering of Common Stock
August 02, 2017 16:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...